What is Predicine?
Predicine operates at the intersection of biotechnology and clinical diagnostics, specializing in next-generation liquid biopsy platforms. The company provides critical molecular insights derived from blood and urine samples, facilitating non-invasive cancer detection and longitudinal monitoring. By offering comprehensive molecular profiling assays, Predicine supports biomarker-driven clinical trials and enhances the efficacy of oncology drug development. Their market position is defined by a commitment to precision medicine, enabling healthcare providers and researchers to access actionable genomic data without the need for invasive tissue biopsies. This technological edge is essential for the modern biopharma landscape, where rapid, accurate patient stratification is paramount for successful therapeutic outcomes.
How much funding has Predicine raised?
Predicine has raised a total of $1.1M across 2 funding rounds:
Debt
$350K
Debt
$703K
Debt (2020): $350K with participation from PPP
Debt (2021): $703K led by PPP
Key Investors in Predicine
PPP
Public-Private Partnership
What's next for Predicine?
With the recent influx of capital, Predicine is well-positioned to accelerate its clinical research solutions and expand its footprint in the oncology drug development ecosystem. The strategic focus will likely shift toward enhancing the sensitivity of their liquid biopsy assays and deepening collaborations with major pharmaceutical entities. As the industry moves toward more personalized treatment paradigms, Predicine's ability to provide real-time molecular monitoring will be a key driver of its long-term growth. Future milestones will likely involve the integration of their diagnostic platform into broader clinical trial networks, further cementing their role as a foundational partner in the advancement of precision cancer therapies.
See full Predicine company page
